Human-Centered Design in AI-Driven Clinical Decision Making

By Sumona Bose

February 6, 2024

Introduction

Artificial intelligence (AI) technologies have revolutionized the healthcare industry, particularly in the realm of clinical decision support systems (CDSS). These AI-empowered systems provide patient-specific recommendations to improve clinical work. However, alongside technical advancements, it is crucial to consider the human, social, and contextual factors that impact the successful implementation and user adoption of AI-CDSS. Human-centered design plays a pivotal role in ensuring the effectiveness and acceptance of these systems. Human centered design in AI has been an important research avenue.

The Role of AI in Clinical Decision Making

AI-empowered CDSS has shown great promise in enhancing patient evaluation and work efficiency. By analyzing vast amounts of data, AI algorithms can identify patterns and provide clinicians with valuable insights for making informed decisions. This technology has the potential to revolutionize healthcare by improving diagnostic accuracy, treatment planning, and patient outcomes.

Understanding User Needs and Experiences

To gain a comprehensive understanding of AI-CDSS, a systematic review was conducted, analyzing 20 relevant articles published between 2011 and 2022. The studies assessed various aspects of AI-CDSS, including effectiveness, user needs, user experience, and other dimensions.

The effectiveness of AI-CDSS was demonstrated through improved patient evaluation and work efficiency. Clinicians reported that AI recommendations helped them make more accurate diagnoses and develop personalized treatment plans. This technology has the potential to significantly enhance clinical decision-making processes.

User needs and experiences were also explored in the reviewed studies. Clinicians expressed the importance of having access to relevant and timely information, as well as the need for user-friendly interfaces. Additionally, factors such as satisfaction, trust, usability, workload, and understandability were found to influence the acceptance and adoption of AI-CDSS.

www.frontiersin.org
Figure 1: System features and examples.

Challenges in Implementing AI-CDSS

Despite the promising nature of AI-CDSS, the systematic review identified several challenges in implementing these systems. Technical limitations, such as algorithmic biases and data quality issues, can hinder the accuracy and reliability of AI recommendations. Workflow misalignment, attitudinal barriers, and informational barriers were also identified as challenges that impact the effective use of AI-CDSS in clinical settings.

Conclusion

The integration of artificial intelligence in clinical decision-making processes holds great potential for improving patient outcomes and work efficiency. However, the successful implementation of AI-empowered clinical decision support systems requires careful consideration of human-centered design principles and addressing the challenges identified in this study. By prioritizing user needs and experiences, healthcare professionals can harness the full benefits of AI technology in healthcare.

Reference url

Recent Posts

Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases
KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ±...